Compare ACADIA Pharmaceuticals Inc. (ACAD) vs Dicks Sporting Goods Inc (DKS) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs Dicks Sporting Goods Inc — how do they compare? ACADIA Pharmaceuticals Inc. trades at $25.82 (market cap $4.49B), while Dicks Sporting Goods Inc trades at $215.83 (market cap $19.97B). The key difference: Dicks Sporting Goods Inc is far larger — about 4.4× ACADIA Pharmaceuticals Inc.'s market cap, and Dicks Sporting Goods Inc pays a 2.24% dividend while ACADIA Pharmaceuticals Inc. pays none. Which is the better fit depends on your goals.
| ACAD | DKS | |
|---|---|---|
Market Cap | $4.49B | $19.97B |
Sector | Health | Consumer Cyclical |
52-Week High | $28.06 | $239.17 |
52-Week Low | $20.06 | $187.78 |
Enterprise Value | $3.69B | $26.76B |
Dividend Yield | — | 2.24% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACAD trades at $26.20, up 0.89% today, with strong analyst consensus (70% buy ratings) and a $33.67 price target. Recent CHMP recommendation for Daybue in Europe (Business Wire, June 26, 2026) drove positive sentiment. The stock shows bullish technical signals with moving averages supporting upside, though RSI levels indicate overbought conditions. Fundamentally, revenue grew to $1.07B in 2025 with a robust net income margin of 34.3%, though Q1 2026 earnings missed expectations.
Outlook remains positive given commercial execution and pipeline catalysts like remlifanserin data, but risks include earnings volatility and regulatory dependencies. The stock offers growth potential in neuropsychiatry markets, balanced by execution risks in clinical trials and competitive pressures.
Dick's Sporting Goods (DKS) trades at $229.02, down 3.03% on the day, with a bullish technical signal from moving averages and neutral oscillators. The stock shows strong fundamentals with consistent earnings beats, a P/E of 22.3, and a net income margin of 4.71%. Recent developments include the launch of ScoreCard+ loyalty program and partnerships with Lids, enhancing growth prospects amid positive analyst sentiment.
The outlook for DKS is positive, supported by robust earnings performance and strategic initiatives. Risks include potential fiduciary concerns highlighted in recent legal investigations and competitive pressures. With a consensus price target of $261, representing a 14% upside, the stock presents a compelling opportunity, though investors should monitor execution risks and market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About Dicks Sporting Goods Inc
Dick's Sporting Goods is a leading omni-channel sporting goods retailer in the US It offers an extensive assortment of authentic sports equipment, apparel, footwear, and accessories through its stores and digital platforms.
Read more on DKS →
